

Title (en)

8-BETA-SUBSTITUTED 16.ALPHA.-FLUORO-ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS

Title (de)

8-BETA-SUBSTITUIERTE 16.ALPHA.-FLUORO-ÖSTRATRIENE ALS SELEKTIV AKTIVE ÖSTROGENE

Title (fr)

16.ALPHA.-FLUORO-ESTRATRIÈNES À SUBSTITUTION 8-BÊTA SERVANT D' ESTROGÈNES SÉLECTIVEMENT ACTIFS

Publication

**EP 2176282 A2 20100421 (EN)**

Application

**EP 08775031 A 20080711**

Priority

- EP 2008059115 W 20080711
- EP 07075600 A 20070712
- EP 08775031 A 20080711

Abstract (en)

[origin: EP2014672A1] The invention refers to 8<sup>2</sup>-substituted estra-1,3,5(10)-triene derivatives of general formula I their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action in the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.

IPC 8 full level

**C07J 1/00** (2006.01); **A61K 31/565** (2006.01); **A61P 5/30** (2006.01)

CPC (source: EP US)

**A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 5/00** (2017.12 - EP); **A61P 5/30** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 15/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/14** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **C07J 1/0062** (2013.01 - EP US); **C07J 1/007** (2013.01 - EP US)

Citation (search report)

See references of WO 2009007454A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA MK RS

DOCDB simple family (publication)

**EP 2014672 A1 20090114**; AR 067507 A1 20091014; AU 2008274198 A1 20090115; BR PI0814207 A2 20150127; CA 2692727 A1 20090115; CL 2008002027 A1 20090116; CN 101687902 A 20100331; CN 101687902 B 20130724; CO 6270230 A2 20110420; CR 11211 A 20100427; CU 20100008 A7 20110527; CU 23885 B1 20130419; CY 1113351 T1 20160622; DK 2176282 T3 20121203; DO P2010000017 A 20100131; EA 017124 B1 20121030; EA 201000097 A1 20100830; EC SP109872 A 20100226; EP 2176282 A2 20100421; EP 2176282 B1 20120822; ES 2393942 T3 20130102; HN 2010000081 A 20130701; HR P20120952 T1 20121231; JP 2010533152 A 20101021; KR 20100037593 A 20100409; MA 31565 B1 20100802; NZ 582490 A 20120330; PA 8789401 A1 20090423; PE 20090825 A1 20090725; PL 2176282 T3 20130628; PT 2176282 E 20121130; RS 52541 B 20130430; SI 2176282 T1 20130228; TN 2010000007 A1 20110926; TW 200911824 A 20090316; UA 99918 C2 20121025; US 2009029957 A1 20090129; UY 31220 A1 20090302; WO 2009007454 A2 20090115; WO 2009007454 A3 20090305

DOCDB simple family (application)

**EP 07075600 A 20070712**; AR P080102978 A 20080711; AU 2008274198 A 20080711; BR PI0814207 A 20080711; CA 2692727 A 20080711; CL 2008002027 A 20080711; CN 200880024423 A 20080711; CO 10002339 A 20100112; CR 11211 A 20100112; CU 20100008 A 20100112; CY 121101099 T 20121114; DK 08775031 T 20080711; DO 2010000017 A 20100112; EA 201000097 A 20080711; EC SP109872 A 20100112; EP 08775031 A 20080711; EP 2008059115 W 20080711; ES 08775031 T 20080711; HN 2010000081 A 20100112; HR P20120952 T 20121121; JP 2010515526 A 20080711; KR 20107000527 A 20080711; MA 32490 A 20100107; NZ 58249008 A 20080711; PA 8789401 A 20080711; PE 2008001165 A 20080711; PL 08775031 T 20080711; PT 08775031 T 20080711; RS P20120516 A 20080711; SI 200830826 T 20080711; TN 2010000007 A 20100107; TW 97126522 A 20080711; UA A201001369 A 20080711; US 17142408 A 20080711; UY 31220 A 20080711